Strive Asset Management LLC Makes New $3.74 Million Investment in Becton, Dickinson and Company $BDX

Strive Asset Management LLC purchased a new stake in shares of Becton, Dickinson and Company (NYSE:BDX) during the third quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 20,000 shares of the medical instruments supplier’s stock, valued at approximately $3,743,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Brighton Jones LLC increased its position in shares of Becton, Dickinson and Company by 98.2% during the 4th quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock valued at $401,000 after purchasing an additional 877 shares during the last quarter. RiverGlades Family Offices LLC bought a new stake in Becton, Dickinson and Company during the second quarter valued at approximately $344,000. Oppenheimer Asset Management Inc. increased its holdings in Becton, Dickinson and Company by 71.4% during the third quarter. Oppenheimer Asset Management Inc. now owns 82,655 shares of the medical instruments supplier’s stock valued at $15,471,000 after buying an additional 34,437 shares during the last quarter. Transcend Capital Advisors LLC raised its position in Becton, Dickinson and Company by 88.2% in the third quarter. Transcend Capital Advisors LLC now owns 5,794 shares of the medical instruments supplier’s stock worth $1,084,000 after acquiring an additional 2,715 shares during the period. Finally, Belpointe Asset Management LLC purchased a new position in shares of Becton, Dickinson and Company during the 3rd quarter worth $650,000. Institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Trading Up 0.1%

Becton, Dickinson and Company stock opened at $176.68 on Tuesday. Becton, Dickinson and Company has a 1 year low of $127.59 and a 1 year high of $187.35. The firm’s 50 day moving average price is $195.28 and its 200-day moving average price is $191.90. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.05 and a quick ratio of 0.58. The stock has a market cap of $50.31 billion, a P/E ratio of 28.82, a PEG ratio of 12.79 and a beta of 0.24.

Becton, Dickinson and Company (NYSE:BDX) last posted its earnings results on Monday, February 9th. The medical instruments supplier reported $2.91 earnings per share for the quarter, beating the consensus estimate of $2.81 by $0.10. The company had revenue of $5.25 billion during the quarter, compared to analysts’ expectations of $5.15 billion. Becton, Dickinson and Company had a net margin of 8.01% and a return on equity of 15.76%. Becton, Dickinson and Company’s quarterly revenue was up 1.6% on a year-over-year basis. During the same period last year, the company posted $3.43 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 12.350-12.650 EPS. On average, equities analysts predict that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company declared that its Board of Directors has approved a share buyback plan on Tuesday, January 27th that allows the company to repurchase $10.00 million in shares. This repurchase authorization allows the medical instruments supplier to buy up to 0% of its shares through open market purchases. Shares repurchase plans are generally an indication that the company’s management believes its shares are undervalued.

Becton, Dickinson and Company Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 31st. Investors of record on Tuesday, March 10th will be given a $1.05 dividend. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.4%. The ex-dividend date is Tuesday, March 10th. Becton, Dickinson and Company’s payout ratio is currently 68.52%.

Insider Buying and Selling

In related news, Director Bertram L. Scott sold 953 shares of the firm’s stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $182.61, for a total value of $174,027.33. Following the completion of the transaction, the director directly owned 36,763 shares of the company’s stock, valued at approximately $6,713,291.43. This trade represents a 2.53% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Michael David Garrison sold 1,610 shares of the company’s stock in a transaction on Thursday, January 15th. The shares were sold at an average price of $207.46, for a total transaction of $334,010.60. Following the sale, the executive vice president directly owned 12,095 shares in the company, valued at approximately $2,509,228.70. The trade was a 11.75% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 3,416 shares of company stock valued at $674,693. 0.40% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on BDX shares. Wall Street Zen cut Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a report on Saturday, November 8th. Wells Fargo & Company lowered their price objective on Becton, Dickinson and Company from $184.00 to $157.00 and set an “equal weight” rating on the stock in a research report on Tuesday, February 10th. Stifel Nicolaus increased their target price on shares of Becton, Dickinson and Company from $210.00 to $215.00 and gave the stock a “buy” rating in a report on Wednesday, January 7th. Barclays began coverage on shares of Becton, Dickinson and Company in a report on Tuesday, February 10th. They set an “overweight” rating and a $202.00 price target on the stock. Finally, Jefferies Financial Group reduced their price objective on shares of Becton, Dickinson and Company from $220.00 to $190.00 and set a “buy” rating for the company in a research note on Tuesday, February 10th. Five equities research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $195.46.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.